|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023981,
umls-concept:C0035647,
umls-concept:C0039736,
umls-concept:C0043210,
umls-concept:C0079083,
umls-concept:C0086589,
umls-concept:C0220825,
umls-concept:C0282460,
umls-concept:C0302600,
umls-concept:C1140680,
umls-concept:C1707455,
umls-concept:C1708063
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2011-7-29
|
|
pubmed:abstractText |
To compare the safety and efficacy of thalidomide in combination with carboplatin to carboplatin alone as a first-line therapy in women with ovarian cancer and to evaluate the anti-angiogenic effects of thalidomide by measurement of surrogate markers of angiogenesis.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0392-2936
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
253-8
|
|
pubmed:meshHeading |
pubmed-meshheading:21797111-Adult,
pubmed-meshheading:21797111-Aged,
pubmed-meshheading:21797111-Aged, 80 and over,
pubmed-meshheading:21797111-Angiogenesis Inhibitors,
pubmed-meshheading:21797111-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21797111-Biological Markers,
pubmed-meshheading:21797111-CA-125 Antigen,
pubmed-meshheading:21797111-Carboplatin,
pubmed-meshheading:21797111-Carcinoma,
pubmed-meshheading:21797111-E-Selectin,
pubmed-meshheading:21797111-Female,
pubmed-meshheading:21797111-Humans,
pubmed-meshheading:21797111-Middle Aged,
pubmed-meshheading:21797111-Neovascularization, Pathologic,
pubmed-meshheading:21797111-Ovarian Neoplasms,
pubmed-meshheading:21797111-Thalidomide,
pubmed-meshheading:21797111-Treatment Outcome,
pubmed-meshheading:21797111-Vascular Cell Adhesion Molecule-1
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
|
|
pubmed:affiliation |
Cancer Research UK Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
